Jennifer Arnold, MD

Jennifer Arnold, MD

Assistant Professor, Neurology
Neuroscience Institute

    About me

    Gender

    Female

    Education & training

    Positions
    Neurologist
    Medical School
    MD, University of Illinois
    Doctorate Degree
    Ph.D. Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign
    Undergraduate Degree
    BS Biology, Southeast Missouri State University
    Residency
    Neurology, University of Michigan
    Fellowship
    Neurodegenerative Diseases, University of Michigan

    Clinical trials

    Trial
    Neurology

    ACDS: A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease

    Active recruiting

    The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study dr

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease (BenfoTeam)

    Active recruiting

    The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine, to determine whether it delays or slows the progression of the symptoms of early Alzheimer’s disease.

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease (BenfoTeam)

    Active recruiting

    The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine, to determine whether it delays or slows the progression of the symptoms of early Alzheimer’s disease.

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1)

    Active not recruiting

    The purpose of this study is to assess the effect of BMS-986446 vs placebo on delay of cognitive memory and functional decline in participants (age 50-80) with early Alzheimer's Disease.

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1)

    Active not recruiting

    The purpose of this study is to assess the effect of BMS-986446 vs placebo on delay of cognitive memory and functional decline in participants (age 50-80) with early Alzheimer's Disease.

    Contact: Stephanie Kohlrus 217-545-3013